SLC5A2 and type 2 diabetes mellitus: Indeed, while the glucose-lowering capacity of empagliflozin is similar to sulfonylurea in patients with T2DM, empagliflozin shows a greater reduction in IL-1β secretion compared to sulfonylurea accompanied by decreased serum insulin and increased serum β-HB (53). A recent meta-analysis demonstrated that SGLT2 inhibitor therapy is associated with a remarkable decrease in the risk of cardiovascular events and renal impairment (54).